United Therapeutics Corp
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
17 / 1361
Position in country
299 / 14179
Return on Assets, %
14.8
-40.3
Net income margin, %
35.3
-180
EBITDA margin, %
45.1
-168.2
Debt to Equity, %
11.6
3.2
Intangible assets and goodwill, %
1.5
0.2
Revenue CAGR 3Y, %
16.2
12.5
Total Equity change 1Y, %
24.7
-9
Revenue Y, % chg
20.2
0
P/E
11.7
31
P/BV
1.8
1.8
P/S
4.7
10.3
EV/S
3.7
7.5
EV/EBITDA
6.9
-1.6
Average Analyst recommendation
Buy
Buy
Average upside forecasts, %
30.8
131.1
Forward P/E
9.5
21.4
Expected dividend per share
0
0
Payout Ratio, %
0
0
Competitors
Ranks
-
United Therapeutics Corp
00%
-
Vertex Pharmaceuticals Inc
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Moderna Inc
00%
-
Alnylam Pharmaceuticals Inc
00%
-
AbbVie Inc
00%
-
Biogen Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
United States of America
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
10945.3
Ticker
UTHR.O
ISIN
US91307C1027
IPO date
1999-06-17
Availability on Russian exchanges
Yes
Reporting for
2024-02-21
Date fact. publication of reports
2023-12-31
Company Description
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. The Company market and sell four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution, which includes the Tyvaso Inhalation System; Orenitram (treprostinil) Extended-Release Tablets; and Adcirca (tadalafil) Tablets. In the United States, the Company also markets and sells an oncology product, Unituxin (dinutuximab) Injection, which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: